|
The document is a report prepared by 3M detailing the sources, environmental dispersion, fate, and effects of sulfonated perfluorochemicals, including PFOA and PFOS, as of March 1, 2000.
|
2000 |
AR226-0620
|
zm4y7bvb4bMzeXgmZmYOQ8R |
51 |
|
Unreadable document.
|
2000 |
AR226-0623
|
JJ2j39N527RLjpxJ1K8jp58L2 |
1 |
|
The document details various reproductive and toxicological studies conducted by 3M Medical Department on perfluorooctane sulfonate (PFOS), including findings on perinatal mortality, cholesterol metabolism effects, and serum concentration responses, as of March 7, 2000.
|
2000 |
AR226-0625
|
8VmNZMpB8aEeNK7gwjLY6ayRK |
11 |
|
The document outlines the objectives of a meeting between the EPA and 3M regarding the management of perfluorinated compounds (PFCs), specifically focusing on product stewardship, risk assessments, and future communications related to 3M's initiatives involving perfluorooctane sulfonyl fluoride and its commercial applications.
|
2000 |
AR226-0626
|
V3wzB2qp0q2GK5bJwkL72DzVZ |
11 |
|
This is a facsimile transmission from Latham & Watkins dated April 27, 2000, intended for Charles Auer and Oscar Hernandez at the EPA, containing confidential information.
|
2000 |
AR226-0628
|
wDVNRENYMoeoa74keVmNDwqx6 |
3 |
|
The document discusses the phaseout of PFOS (perfluorooctane sulfonate) and highlights an important development regarding its status as a persistent, bioaccumulative, and toxic chemical, with plans to engage the OECD Secretariat for further discussion.
|
2000 |
AR226-0629
|
aB9mMbwG62QQopxgymRO14Xn9 |
6 |
|
The document is a letter from the EPA's Charles M. Auer to Dr. William A. Weppner of 3M Corporation, requesting assistance in arranging a meeting with global fluorochemical manufacturers regarding recent developments on PFOS.
|
2000 |
AR226-0630
|
5DmgNVXRV36rRKXN5DXnJo9M0 |
1 |
|
Dainippon Ink & Chemicals, Inc. communicated to the EPA their intention to phase out products containing PFOS in response to regulatory discussions, while seeking clarification on potential regulations affecting their customers who export PFOS-containing products to the U.S.
|
2000 |
AR226-0631
|
b5kamg6Y6OpMvk4qeEE4MxeYk |
2 |
|
The document discusses the OECD's approach to assessing PFOS and its derivatives in light of 3M Corporation's decision to phase out production for most uses, highlighting collaborative efforts among member countries to prepare a screening level risk assessment addressing human and environmental hazards, uses, and potential substitutes.
|
2000 |
AR226-0632
|
jRGNgpbQkB41QQykQYmb0J8O |
2 |
|
The document is a correspondence from the EPA to 3M regarding the submission of test data on perfluorochemicals, specifically outlining the requirements for acute systemic toxicity studies, skin and eye irritation studies, and bibliographic listings of prior studies, with a focus on studies conducted from 1976 onwards.
|
2000 |
AR226-0633
|
LKBY72QBXZmg8RVXo7E4BLj8g |
2 |
|
The document is a request from the EPA for information on perfluorinated chemicals, specifically focusing on PFOA and PFOS, including health effects, environmental studies, and exposure data, with deadlines for submission of the requested information.
|
2000 |
AR226-0634
|
wDVR9XGgwGmvYNaVby59QKnLo |
2 |
|
The document is a follow-up email from Barbara Leczynski of the EPA to 3M regarding a meeting on April 28, 2000, discussing the extension for 3M to provide information on PFOS, expectations for interim reports, and the submission of relevant data to evaluate the hazards and risks associated with PFOS and other perfluorinated compounds.
|
2000 |
AR226-0636
|
bBK6wwQzaa3DQn5ejD5EQQ3j6 |
1 |
|
The document is a request from the EPA for 3M to provide complete final reports and relevant information on PFOS and other perfluorinated compounds, including health and environmental effects studies, within specified deadlines.
|
2000 |
AR226-0635
|
93eJOMbvz08OJZRYxkjd0VRYD |
2 |
|
3M is coordinating a meeting with the EU Commission to discuss PFOS and will provide additional information on PFOS mixtures, PFOA, and other derivatives by specified dates in May and June 2000.
|
2000 |
AR226-0637
|
DM32yVR6E1JzKn9y92mGb3yVM |
1 |
|
The document presents an overview of PFOS (perfluorooctane sulfonic acid), detailing its production by 3M Corporation, widespread environmental and biological presence, and significant health effects observed in studies, including developmental toxicity in rats and accumulation in humans and wildlife.
|
2000 |
AR226-0639
|
VGJyYGOj3gKZXGLMaoOpNGwgo |
3 |
|
3M announced it is phasing out the production of perfluorooctanyl chemistry, including certain Scotchgard products and fire-fighting foams, due to increasing scrutiny on persistent materials, despite existing evidence suggesting these compounds do not pose significant health or environmental risks.
|
2000 |
AR226-0641
|
102B1zpL17Jn3ZZe9eqbB4Jqd |
2 |
|
The final report from 3M Environmental Laboratory indicates that a single-dose dermal absorption study of the fluorochemical FC-120 (T-6052) in rabbits showed no significant organic fluorine absorption at the highest dose of 1000 mg/kg, with only trace amounts detectable, suggesting the doses were insufficient to assess dermal absorption effectively.
|
2000 |
AR226-0234
|
qdXBDnKaBGpZqq3gZw3NYBwV5 |
183 |
|
The document contains various toxicity and genotoxicity study reports on N-methyl perfluorooctanesulfonamide (N-MeFOSA) conducted by Hazleton Laboratories America, Inc. for 3M, detailing acute oral toxicity, primary dermal irritation, primary eye irritation, and microbiological mutagenicity assays.
|
2000 |
AR226-0242
|
jmryBrjzoLNqeX9YNe7zVLObp |
51 |
|
Dainippon Ink & Chemicals Inc. is requesting a meeting with the U.S. EPA on September 15, 2000, to discuss issues related to PFOS, with Mr. Ehara attending on behalf of the company.
|
2000 |
AR226-0642
|
7R6nxmxwpE3JJBXGvMOwXvRJj |
1 |
|
The document is a letter from the EPA to Dainippon Ink & Chemicals, Inc. regarding their decision to phase out perfluorooctyl sulfonate (PFOS) for certain uses, while expressing the Agency's willingness to discuss critical uses and potential substitutes due to concerns about PFOS's persistence in the environment and its potential health risks.
|
2000 |
AR226-0643
|
MMvKZQNpV43Z0Ez0gNYQm96ja |
2 |
|
3M submitted additional information to the EPA regarding perfluorooctane sulfonates and related compounds, while designating one specific environmental study as confidential business information (CBI).
|
2000 |
AR226-0644
|
oe6GN1x9Ne8x0EjMqJ6p73Xro |
11 |
|
The document is a final report of a 4-week range-finding dietary toxicity study conducted by Covance Laboratories on N-Methyl Perfluorooctanesulfonamido Ethanol (N-MeFOSE, T-6314) for the sponsor 3M.
|
2000 |
AR226-0616
|
mBYxK5321eoOaG3we1jLbDGpb |
374 |
|
The document contains attachments related to studies and information on perfluorooctane sulfonate (PFOS) and its related compounds, including acute toxicity, genotoxicity, and repeated-dose toxicity studies conducted by Hazelton Laboratories and International Research and Development Corporation.
|
2000 |
AR226-0249
|
oMooVe78Oj6Q7xp5NXYNEdJxX |
20 |
|
3M Corporation announced its decision to voluntarily discontinue the manufacture of 90 PFOS chemicals, including those used in AFFF products, by the end of 2002 due to concerns about PFOS's persistence and toxicity, prompting the EPA to propose a significant new use rule requiring notification for any future manufacturing or importing of these chemicals.
|
2000 |
AR226-0998
|
rYBXvkLgyV0ovKoMNmx4QYVE |
5 |
|
The document is a final report on a 13-week dietary toxicity study of N-Methyl Perfluorooctanesulfonamido Ethanol (N-MeFOSE, T-6314) conducted in rats, sponsored by 3M and performed by Covance Laboratories Inc.
|
2000 |
AR226-0991
|
x6RQVNn4562yRQEpgXEo7goE |
560 |
|
Following negotiations, 3M announced it will voluntarily phase out perfluorooctanyl sulfonate (PFOS) chemistry used in various products, with the EPA indicating it will monitor the situation and take further regulatory actions if necessary.
|
2000 |
AR226-0000
|
Byq4d5v0X3zwgXemXxLGY08Lm |
1 |
|
This document is a correspondence from Larry R. Zobel of 3M to Dr. Oscar Hernandez at the EPA, providing additional documents related to studies on PFOS and PFOA that were inadvertently omitted from a previous package.
|
2000 |
AR226-0001
|
v1zO4VjERBm0x9rg4x8dgyrRE |
1 |
|
This letter from 3M's Medical Director, Larry R. Zobel, clarifies findings from a two-generation reproduction study on potassium perfluorooctanesulfonate (PFOS), stating that there were no significant effects on pup survival or growth at the 0.4 mg/kg/day dose, contrary to previous report language.
|
2000 |
AR226-0002
|
jNgGvaY0G1LkQZdpGq4oB76gp |
6 |
|
3M is providing the EPA with additional voluntary information on perfluorooctanesulfonate (PFOS), including studies on pharmacokinetics, teratology, and epidemiology, as part of ongoing discussions regarding fluorochemistry.
|
2000 |
AR226-0003
|
GKg1vGYakJOkxKx9RZv8N9rm7 |
10 |
|
The document details a series of studies conducted by 3M on dermal absorption and pharmacokinetics of perfluorooctanesulfonate (PFOS) in New Zealand white rabbits to assess the absorption capacity of low-molecular-weight manufacturing residuals and establish detection limits for PFOS and fluoride ion as markers of dermal absorption.
|
2000 |
AR226-0009
|
6B5157Eej2koXOVywd9zLZmB9 |
4 |
|
The document summarizes an oral developmental toxicity study of potassium perfluorooctanesulfonate (PFOS) in rats, conducted by Riker Laboratories, which found maternal toxicity at the highest dose but no evidence of fetal toxicity, although a significant increase in developmental eye abnormalities was noted across all dose groups.
|
2000 |
AR226-0013
|
mBqgj18qwgB66OO7pkj44nOBd |
3 |
|
The document is a final report from 3M Environmental Laboratory detailing an analytical study on the pharmacokinetics of the fluorochemical FC-95 (T-6049) in rabbits, which confirmed the presence of perfluorooctanesulfonate in liver and serum after intravenous dosing.
|
2000 |
AR226-0012
|
2EVa9Ny5BrD7nV8V8RBBz5bR |
82 |
|
This document is a final report from 3M Environmental Laboratory detailing an analytical study on the dermal absorption and toxicity of FC-95 (T-6049), a potassium salt of perfluorooctanesulfonic acid (PFOS), in rabbits, concluding that no detectable dermal absorption occurred at the tested low dose levels.
|
2000 |
AR226-0011
|
NDmX1EY2j5rZw3X1BD9a9X4E |
95 |
|
The document is a supplemental submission detailing the fluorochemical characterization of surface water samples from multiple cities, including Columbus, GA, Cleveland, TN, Decatur, AL, Mobile, AL, Pensacola, FL, and Port St. Lucie, FL, as part of a multi-city study conducted by various laboratories, including Centre Analytical Laboratories and Battelle Memorial Institute.
|
2000 |
AR226-0670
|
0grn58DmYdvkzBYKeKaQ0bBdm |
11 |
|
The document outlines various analytical methods developed by 3M Environmental Laboratory for the extraction and analysis of Potassium Perfluorooctanesulfonate (PFOS) and other fluorochemicals from serum, liver, and urine using HPLC-Electrospray/Mass Spectrometry, detailing method numbers and adoption dates.
|
2000 |
AR226-0024
|
BjELLb6MGng5pvwvXwe1Bvem |
15 |
|
Pace Analytical Services, Inc. conducted resampling for PFOS and other fluorochemicals in Port St. Lucie, Florida, under contract with 3M to confirm baseline data from a previous study.
|
2000 |
AR226-0680
|
8rngrJxK9pybrN9JdBL3dJ1B |
13 |
|
The document discusses the monitoring of perfluorinated surfactants, particularly PFOA and PFOS, in biota and surface water samples following a 2000 accidental release of fire-fighting foam at L. B. Pearson International Airport into Etobicoke Creek, highlighting concerns over their environmental persistence and toxicity.
|
2000 |
AR226-1061
|
JJxJaV1Zn7o9qV3KNvrndoRDa |
8 |
|
This document is a correspondence from 3M confirming the submission of a non-confidential version of a toxicological study on perfluorooctane sulfonates to the EPA, following a request for such information.
|
2000 |
AR226-0037
|
DGp8ay1GDnV4q0DKOzgm0qyjQ |
1 |
|
3M is requesting a one-week extension to respond to the EPA's request for information on perfluorooctane sulfonic acid (PFOS) due to operational disruptions and seeks clarification on related questions before their upcoming meeting with the EPA.
|
2000 |
AR226-0041
|
Y3XO6VRdj1DJjZZO1ZJ6KwON |
1 |
|
This is a letterhead cover page from the EPA's Office of Prevention, Pesticides and Toxic Substances, with no analytical content retained in the OCR.
|
2000 |
AR226-0040
|
dB74GdMQoepJp2O36MxeGrN0 |
5 |
|
This document is a letter from 3M to the EPA detailing the voluntary submission of data on perfluorooctane sulfonic acid (PFOS) and its salt forms, emphasizing that the majority of their fluorochemical production involves higher molecular weight derivatives and that they are actively working to reduce manufacturing residuals.
|
2000 |
AR226-0042
|
rxgpLQOM2xgdeBnOEb47Q1eaG |
2 |
|
3M is providing the EPA with additional voluntary information on perfluorooctane sulfonates, including various CAS numbers and summaries of studies related to their environmental properties and health effects, as part of ongoing discussions about fluorochemistry.
|
2000 |
AR226-0044
|
yba6aBBvV2dvxY571Mm68vEV |
31 |
|
This document provides a voluntary use and exposure information profile for perfluorooctane sulfonates (PFOS) and their various salt forms produced by 3M Company, detailing their chemical identification, manufacturing process, and estimated off-site distribution.
|
2000 |
AR226-0043
|
qaB8KNN8Q0ZJvGoj2KNgYrgQn |
30 |
|
The document outlines various reports and studies conducted by 3M regarding the health effects and serum levels of Perfluorooctane Sulfonate (PFOS) in male employees at their fluorochemical production facilities, including epidemiologic investigations and assessments of fluorochemical exposure.
|
2000 |
AR226-0030
|
Y9pjBmZ3QqO8NY83Mk6BmqpL8 |
190 |
|
The document contains various laboratory reports and summaries related to the physical and chemical properties, solubility, and environmental fate of perfluorooctanesulfonate (PFOS) conducted by Wildlife International, Ltd. and 3M Environmental Lab.
|
2000 |
AR226-0055
|
zdXvRqVGm5QBykqz4YLzX3476 |
39 |
|
The document outlines the design and methodology of a Multi-City study submitted to 3M Environmental Laboratory, aimed at gathering preliminary data on the dispersion of fluorochemical compounds, including PFOA, in the environment, their uptake into food, and their presence in drinking water to assess potential human exposure sources.
|
2000 |
AR226-0063
|
5k8xyYQ7j9OGo0E3eVGvNMK8z |
7 |
|
The document details a dietary acute study on the effects of perfluorooctanesulfonate (PFOS) on mallard ducks, conducted by Whistling Wings, Inc., with a test substance purity of 90.49% and utilizing specific GLP methods to assess toxicity and stability over a 5-day exposure period.
|
2000 |
AR226-0102
|
e5j8g9NonMV6LX4VBea9Rg4og |
8 |
|
This document contains various studies and reports on the genotoxicity and mutagenicity of perfluorooctane sulfonate (PFOS) conducted by different laboratories, including Ames tests and chromosomal aberration assessments, primarily associated with 3M Company.
|
2000 |
AR226-0128
|
2q88Kjqj5pXVL4KMOzJ2VN37R |
12 |
|
This is a final report prepared by Battelle Memorial Institute for 3M Specialty Materials, detailing life-cycle waste stream estimates for sulfonated perfluorochemicals in the U.S. from 1997.
|
2000 |
AR226-0681
|
GE21LzLdw1ekEZwZX4Nd5dN7 |
11 |
|
3M is providing the EPA with information on perfluorooctane sulfonates (PFOS) mixtures, specifically noting that potassium perfluorooctane sulfonate is intentionally added to their aqueous fire fighting foam (AFFF) products at low levels, and that further studies on AFFF products may have limited relevance to the hazard profile of PFOS.
|
2000 |
AR226-0682
|
Rp5qyonB3X9GG5v37mgn59Don |
41 |
|
The document evaluates mutagenicity studies on perfluorooctanesulfonate (PFOS) conducted by Covance and Corning Hazleton to assess the potential mutagenic/genotoxic risk posed by PFOS, a degradation product of perfluorooctanesulfonylfluoride used by 3M.
|
2000 |
AR226-0135
|
zdOrNywgO5xX8BEDdGzwN8gVR |
12 |
|
The document contains attachments related to various toxicity studies of Perfluorooctane Sulfonate (PFOS) and Fluorad Fluorochemical Surfactant FC-95 conducted by the International Research and Development Corporation and Covance Laboratories, detailing findings from subacute and chronic toxicity studies in rhesus monkeys and rats.
|
2000 |
AR226-0137
|
qd4V55G17DZMKogLKYgGy4gYG |
41 |
|
The document details the findings from a microscopic review of liver sections from rats in a chronic PFOS study, indicating centrolobular hepatocyte hypertrophy as a compound-related change, with specific observations on the presence of lipid type cytoplasmic vacuoles in certain groups, leading to a determination of NOAEL and NOEL for liver histologic changes.
|
2000 |
AR226-0141
|
Z4LoyobZZ85Vx0xQ35p0kVGGd |
11 |
|
This document details an acute toxicity test of a mixture containing 3% perfluorooctanesulfonate (PFOS) on the aquatic invertebrate Corophium volutator, conducted using ASTM E1367-90 methodology, with results potentially influenced by impurities in the test sample.
|
2000 |
AR226-0697
|
QJ0ZrBdexVdJyqx6Vrvb2wGb5 |
34 |
|
The document contains an exploratory 28-day oral toxicity study on PFOS and other chemicals, submitted by 3M under a claim of confidentiality, detailing the effects of these substances in rats.
|
2000 |
AR226-0153
|
25VQMEqYyBx1JVBZGpnRmw95 |
1 |
|
The document contains various pharmacokinetic studies related to perfluorooctane sulfonate (PFOS) conducted by 3M, including skin absorption studies in rabbits and analytical data on serum measurements from in-life studies in rats.
|
2000 |
AR226-0154
|
e5vp9bMD02YxmvMoV3Y5Vw6aq |
6 |
|
This document details an acute toxicity test of a mixture containing perfluorooctanesulfonate (PFOS) on the aquatic invertebrate Corophium volutator, using a method based on ASTM E1367-90, with results potentially affected by the presence of impurities in the test sample.
|
2000 |
AR226-0730
|
5RgQ93ogZVZJ1w5p387G9JwD |
34 |
|
This document from 3M provides serum measurements for perfluorooctanesulfonate (PFOS) from two pharmacokinetic studies conducted on rats, detailing the analytical results and offering assistance to the EPA in understanding the toxicological information.
|
2000 |
AR226-0160
|
VKyEyZb3GOXbzvDg4oDJZ57V8 |
22 |
|
This final report details a pharmacokinetic study conducted by 3M on the perfluorinated compound FC-99 (T-6053) in rabbits, finding that fluorine was detected in liver tissue after a single intravenous dose of 20 µg/kg, indicating that the perfluorooctanesulfonate salt form does not affect the availability of total organic fluorine in the
|
2000 |
AR226-0157
|
QM4NegreReRMbgOLkarj3XmJ6 |
88 |
|
The document is a final report from 3M Environmental Laboratory detailing a single-dose dermal absorption/toxicity study of the perfluorinated compound FC-99 (T-6053) in rabbits, which found no significant differences in liver fluorine levels between treated and control groups, indicating low dermal absorption of the substance.
|
2000 |
AR226-0158
|
gaxkQK2jg9wbwgjJX0pJawYDe |
135 |
|
The document outlines research proposals and studies by Kendall B. Wallace at the University of Minnesota Duluth focused on understanding the biochemical and molecular mechanisms of perfluoroalkyl compounds, particularly perfluorooctane sulfonate (PFOS), with the goal of establishing reliable biomarkers for exposure and biological effects related to health risks.
|
2000 |
AR226-0165
|
VG6O186xezYB5KO2gaE7RYzDg |
12 |
|
This report details the effects of a single acute dose of PFOS (40 mg/kg) and N-EtFOSE (160 mg/kg) on catalase and acylCoA oxidase gene expression and enzyme activity in liver tissue from rats and guinea pigs, as part of a study conducted by 3M.
|
2000 |
AR226-0171
|
G5Oem37jNoadbqrYoNXjokken |
6 |
|
The document discusses various studies and analyses related to perfluoroctane sulfonate (PFOS) in human sera, focusing on blood fluoride levels and the implications of organic fluorine concentrations in relation to exposure and industrial hygiene controls.
|
2000 |
AR226-0174
|
KVk7zN1maQazbB2kmvmNbz20 |
7 |
|
The document is a final report of a pilot teratology study in rats (Project No. 154-158) conducted by Hazleton Laboratories for 3M, focusing on the effects of perfluoroctane sulfonate (PFOS).
|
2000 |
AR226-0173
|
gbmx49pXL3aJYMN4bM164RMNa |
48 |
|
The document outlines ongoing studies related to Perfluorooctane Sulfonic Acid Potassium Salt (PFOS) being conducted by Covance Laboratories and 3M, including a 104-week dietary chronic study in rats and various toxicity and pharmacokinetic studies, with interim data provided for these investigations.
|
2000 |
AR226-0179
|
8VmG6jaBy2oz8ymMp9KYe2Emk |
12 |
|
This document outlines a research project by 3M, led by Deanna J. Luebker, investigating the mechanism by which perfluorooctane sulfonic acid (PFOS) induces adverse effects on peri-/postnatal development in rats, specifically focusing on its inhibition of HMG-CoA reductase and potential toxicity mitigation through co-administration of mevalonate.
|
2000 |
AR226-0183
|
KDx86Xbva76OwjkYp628eN8X |
16 |
|
The document outlines ongoing environmental studies on perfluorooctanesulfonates (PFOS) being conducted by various laboratories, including 3M Environmental Laboratory and Wildlife International, with expected completion dates in 2000 for studies on physical/chemical properties, environmental fate, transport, and ecotoxicity tests.
|
2000 |
AR226-0184
|
Gm1vo5z4NaQvb5Orn3GaNKQpV |
12 |
|
The document details an acute toxicity test of a PFOS-containing mixture (FC-602) on the aquatic invertebrate Corophium volutator, conducted using standard methods to assess the toxicity of the fluorochemical component.
|
2000 |
AR226-0847
|
10yj86zXxg01Nj4M8pd6bx04j |
35 |
|
The document details an acute toxicity test of a mixture containing 1.30% perfluorooctanesulfonate (PFOS) on the aquatic invertebrate Corophium volutator, conducted using ASTM E1367-90 methodology, with results potentially influenced by impurities in the test sample.
|
2000 |
AR226-0861
|
rBMgZKz7zOyQ8Q9dRL7OE4rxr |
34 |
|
The document contains attachments to a letter discussing various studies and information on acute toxicity and genotoxicity related to perfluorooctane sulfonate (PFOS) and its derivatives, including tests conducted by Biosearch, Inc. and Hazelton Washington.
|
2000 |
AR226-0291
|
zoGqppdxaobJJRVmMLzep8L0B |
4 |
|
The document includes various studies and tests conducted by Riker Laboratories and other institutions on the acute toxicity, immunotoxicity, genotoxicity, and repeated-dose toxicity of N-ethylperfluorooctane sulfonamidoethyl acrylate (T-3493), a perfluorinated compound associated with 3M.
|
2000 |
AR226-0304
|
rp7JnEa7G8x3NKqQg9grEwx4G |
10 |
|
The document details acute toxicity studies conducted by Riker Laboratories on N-ethyl perfluorooctane sulfonamido ethyl methacrylate (T-3494), including oral toxicity, skin irritation, and ocular irritation tests in albino rats and rabbits, as part of a safety evaluation for 3M.
|
2000 |
AR226-0312
|
jy3Ry3eOXoEggKg92pBNb8EN5 |
10 |
|
This document contains studies and evaluations regarding the mutagenic activity of N-methylperfluorooctane sulfonamidoethyl acrylate (T-5869) conducted by NOTOX, including results from the Ames Salmonella test and chromosome aberration tests, all compliant with GLP standards.
|
2000 |
AR226-0317
|
6BBoN297mVo3o8Q2p3Y1Rm7K6 |
24 |
|
The document contains attachments related to studies on the acute toxicity and pharmacokinetics of perfluorooctane sulfonate (PFOS) and its derivatives, specifically detailing various toxicity tests conducted by 3M and other laboratories.
|
2000 |
AR226-0320
|
JJ2p3D5EvGxRzvmaREkM00nYv |
32 |
|
3M submitted a revised "Use and Exposure Information Profile" for perfluorooctane sulfonic acid (PFOS) to the EPA, providing additional details on their environmental and industrial hygiene management of the substance at their manufacturing facilities.
|
2000 |
AR226-0927
|
YGRVkw92Ybz8xBn6q7JYYeG0N |
1 |
|
The document is a letter from the EPA to 3M Company, informing them about the enclosed TSCA Administrative Record on PFOS and related compounds, which includes submissions from 3M and DuPont, and outlines future submission protocols.
|
2000 |
AR226-0929
|
damXmEO1Q2NOxg82D16r71kDq |
1 |
|
The document is a letter from 3M to the EPA detailing the CAS numbers and names of perfluorooctanyl chemistry products that 3M plans to phase out, as part of their commitment to discontinue manufacturing these substances.
|
2000 |
AR226-0931
|
GKwBLnjMrx5EOnKmvyG505xZV |
5 |
|
Dainippon Ink & Chemicals, Inc. is confirming a meeting with the U.S. EPA on September 15th regarding PFOA/PFOS, with representatives attending due to the absence of the President of the Additives & Chemicals Division.
|
2000 |
AR226-0933
|
DDzd1Gkba61e898jkB6z33MRo |
1 |
|
This document is a letter from 3M to the EPA formalizing a response regarding the non-confidential status of chemical names and phase-out dates for perfluorinated compounds, specifically stating that the complete phase-out dates for Industrial Surfactants and Fire Fighting Foams are not considered confidential business information.
|
2000 |
AR226-0932
|
dn45wQEGGgOR0BKD1Dr1o0Qxq |
3 |
|
Dainippon Ink & Chemicals Inc. is requesting a meeting with the U.S. EPA on September 15, 2000, to discuss the issue of PFOS, acknowledging the EPA's support for 3M's decisions regarding the substance.
|
2000 |
AR226-0934
|
dn9NrMgZnzbNnYK3Yd5Ndd6GR |
2 |
|
The document provides a voluntary use and exposure information profile for perfluorooctane sulfonate (PFOS) and its various salt forms produced by 3M Company, detailing their chemical identification, manufacturing processes, and distribution estimates.
|
2000 |
AR226-0928
|
5L8w5gqZewZZREVznK3DK1YNN |
34 |
|
The document is a communication from Deltoppon Ink & Chemicals Inc. to the U.S. EPA regarding a meeting scheduled for September 15, 2000, to discuss various issues including PFOA and other perfluorinated compounds.
|
2000 |
AR226-0935
|
V3NgpN025RJ7QKMdLGRMx6kLZ |
1 |
|
The document is a letter from the EPA's Office of Prevention, Pesticides and Toxic Substances to Masanobu Yumoto of Dainippon Ink & Chemicals, discussing a meeting to address technical uses of PFOS and clarifying that the meeting will not involve negotiations.
|
2000 |
AR226-0936
|
Yj4a78e5RNzp0GVB9n1NjrXEK |
1 |
|
This document discusses Kidde Fire Fighting's foam concentrate products, clarifying that they do not contain PFOS due to their use of specialty fluorochemicals from the TFE process, and addresses concerns regarding the EPA's consideration of extending the phase-out plan for 3M's foam concentrates.
|
2000 |
AR226-0940
|
XOqJKOLB95G0KqXr2bQ2o6dKd |
1 |
|
IKEA's Quality Department inquired about the environmental and health effects of DuPont's Teflon-based finish in comparison to PFOS, as they are phasing out products treated with 3M's Scotchgard due to EPA's concerns over perfluorinated compounds.
|
2000 |
AR226-0941
|
NNm9Eqg5zE7GmMpXKexBdzRGD |
1 |
|
The Boeing Company is informing the EPA that it has been using FC-98, a fluorinated compound essential for hydraulic fluid in aircraft, and is concerned about its impending phase-out by 3M, the sole manufacturer, as there are no alternatives available.
|
2000 |
AR226-0943
|
NE9KEXnqp547LOQxvMYy9k1QE |
5 |
|
The document is a note summarizing a meeting held on September 15, 2000, to discuss alternatives to PFOS for carpet treatment, attended by representatives from Shaw Industries and the EPA.
|
2000 |
AR226-0945
|
KJwV4B6Qp8kMJ20G5qkQOLR8w |
1 |
|
The document is a revised PFOS hazard assessment from October 23, 2000, by Karen Lannon, which includes minor textual corrections from the original version but states that the conclusions remain unaffected.
|
2000 |
AR226-0946
|
qdE0p01R4X5Zvy1bBeMJgBRLK |
29 |
|
3M is providing additional voluntary information to the EPA regarding perfluorooctane sulfonates and related compounds, including various CAS numbers and chemical forms, as part of ongoing discussions about fluorochemistry.
|
2000 |
AR226-0333
|
qddeLBwY5qg4xO8Q8j6bbx8E5 |
20 |
|
The document is a status report on the Telomer Research Program presented to the U.S. EPA on October 23, 2000, detailing the program's organization, guiding principles, and management structure focused on data gathering related to telomer manufacturers, including companies like DuPont and Daikin.
|
2000 |
AR226-0947
|
g2zxGw04wGD0VJ2ee6VDX54mL |
153 |
|
The document details an acute inhalation toxicity study of T-2306 CoC, a perfluorinated compound from 3M, conducted on rats to determine its median lethal concentration (LC50).
|
2000 |
AR226-0954
|
5yYQ6ZELQJ54Q8JBzXbeBZ10 |
42 |
|
This document reports on a pharmacokinetic study of T-6246 (FC-95) in rabbits, revealing that the half-life of perfluorooctanesulfonate anion in serum and liver is one month or greater, with detectable fluorine levels in serum after doses of 0.12 mg/kg and 0.60 mg/kg but not after 0.012 mg
|
2000 |
AR226-0948
|
6ba7QEdxZoDdqNvxevqnkdQEo |
281 |
|
Following negotiations, 3M announced it will voluntarily phase out perfluorooctanyl sulfonate (PFOS) chemistry used in various products, with the EPA indicating it will monitor the situation and take further regulatory actions if necessary.
|
2000 |
AR226-0000
|
dYJo0wb5k093M2QdONz7NkbDR |
1 |
|
This document is a correspondence from Larry R. Zobel of 3M to Dr. Oscar Hernandez at the US EPA, providing additional documents related to studies on PFOS and PFOA that were inadvertently omitted from a previous package.
|
2000 |
AR226-0001
|
k6vp1Jyo3oBMEE4xrLaYaBrjE |
1 |
|
The document contains studies and information regarding the acute toxicity of perfluorooctane sulfonate-related compounds, specifically focusing on T-3421 (PFOS) and FOSA, conducted by Riker Laboratories for 3M between 1983 and 1999.
|
2000 |
AR226-0963
|
rx4eRgdo52QrOynrdmwD47rzE |
13 |
|
The document contains attachments to a letter to C. Auer dated May 18, 2000, discussing studies and information related to perfluorooctane sulfonate (PFOS) and N-ethyl perfluorooctanesulfonamide (N-EtFOSA) that are in 3M's possession, believed to be part of the FIFRA docket.
|
2000 |
AR226-0377
|
gaoGgoELOLz7dKqErGDDevpXJ |
2 |
|
3M submitted additional information to the EPA regarding perfluorooctane sulfonates and related compounds, including details on N-ethylperfluorooctane sulfonamidoethanol, N-methylperfluorooctanesulfonamidoethyl acrylate, and other perfluorinated compounds.
|
2000 |
AR226-0378
|
aJ578JLXe6oKb0jrxk9aKNQ2B |
8 |
|
The document contains attachments to a letter regarding toxicology studies on PFOA, detailing various acute toxicity studies conducted on rats and rabbits by different laboratories, including inhalation and oral toxicity assessments.
|
2000 |
AR226-0417
|
xjb1yeR0RRNY70ooZ2985qnvy |
7 |
|
3M is providing the EPA with supplemental information on perfluorooctanoic acid (PFOA) and perfluorooctane sulfonates (PFOS) that includes studies on their environmental and health effects as part of ongoing discussions regarding fluorochemistry.
|
2000 |
AR226-0416
|
jmON1rv6mnJOzDGMeQGXM1m0Q |
28 |
|
The document contains attachments related to toxicology studies and mutagenicity evaluations of PFOA and its derivatives conducted by various laboratories, including reports on cell transformation, cytotoxicity, and chromosomal aberrations.
|
2000 |
AR226-0428
|
k6YOvr6bpoK5kga0e2XbbmqnE |
19 |